Taigen Biopharmaceuticals Holdings Ltd - Asset Resilience Ratio
Taigen Biopharmaceuticals Holdings Ltd (4157) has an Asset Resilience Ratio of 80.28% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 4157 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Taigen Biopharmaceuticals Holdings Ltd's Asset Resilience Ratio has changed over time. See 4157 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Taigen Biopharmaceuticals Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Taigen Biopharmaceuticals Holdings Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$813.55 Million | 80.28% |
| Total Liquid Assets | NT$813.55 Million | 80.28% |
Asset Resilience Insights
- Very High Liquidity: Taigen Biopharmaceuticals Holdings Ltd maintains exceptional liquid asset reserves at 80.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Taigen Biopharmaceuticals Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Taigen Biopharmaceuticals Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Taigen Biopharmaceuticals Holdings Ltd (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Taigen Biopharmaceuticals Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 80.53% | NT$945.68 Million ≈ $29.79 Million |
NT$1.17 Billion ≈ $37.00 Million |
+26.60pp |
| 2023-12-31 | 53.94% | NT$663.34 Million ≈ $20.90 Million |
NT$1.23 Billion ≈ $38.75 Million |
-8.76pp |
| 2022-12-31 | 62.69% | NT$656.39 Million ≈ $20.68 Million |
NT$1.05 Billion ≈ $32.99 Million |
+22.52pp |
| 2021-12-31 | 40.17% | NT$559.46 Million ≈ $17.63 Million |
NT$1.39 Billion ≈ $43.88 Million |
-8.34pp |
| 2020-12-31 | 48.51% | NT$269.92 Million ≈ $8.50 Million |
NT$556.45 Million ≈ $17.53 Million |
-6.07pp |
| 2019-12-31 | 54.57% | NT$516.33 Million ≈ $16.27 Million |
NT$946.11 Million ≈ $29.81 Million |
+1.17pp |
| 2018-12-31 | 53.40% | NT$634.27 Million ≈ $19.98 Million |
NT$1.19 Billion ≈ $37.42 Million |
-3.22pp |
| 2017-12-31 | 56.62% | NT$861.84 Million ≈ $27.15 Million |
NT$1.52 Billion ≈ $47.96 Million |
-8.75pp |
| 2016-12-31 | 65.37% | NT$538.32 Million ≈ $16.96 Million |
NT$823.45 Million ≈ $25.94 Million |
+2.70pp |
| 2015-12-31 | 62.67% | NT$391.97 Million ≈ $12.35 Million |
NT$625.46 Million ≈ $19.71 Million |
-17.61pp |
| 2014-12-31 | 80.28% | NT$881.62 Million ≈ $27.78 Million |
NT$1.10 Billion ≈ $34.60 Million |
+65.56pp |
| 2013-12-31 | 14.72% | NT$71.61 Million ≈ $2.26 Million |
NT$486.49 Million ≈ $15.33 Million |
+4.87pp |
| 2012-12-31 | 9.85% | NT$72.31 Million ≈ $2.28 Million |
NT$733.95 Million ≈ $23.12 Million |
-- |
About Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more